Invivyd Reports Second Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollme

Event · Earnings
Original reporting
Published Aug 13, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IVVD
Neutral
medium confidence
Mentioned
$IVVD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IVVDNeutralMed
01

Why it matters

Traders should focus on (1) the updated cash runway and (2) the stated schedule for VYD2311 pivotal top-line data (late Q3 2026) while also weighing the regulatory overhang from the EUA termination advanced notice for PEMGARDA and the company’s FDA dialogue on next steps.

02

Market read

A primary filing that combines a modestly positive commercial datapoint (PEMGARDA revenue growth) with a meaningful regulatory risk (EUA termination notice) and a concrete clinical catalyst window (VYD2311 top-line late Q3 2026).

03

What to watch

R&D expense jumped to $29.4M from $9.6M YoY, which could pressure valuation if pivotal timelines slip or if FDA next steps for PEMGARDA reduce monetization options.

Relevance 7/10Novelty 7/10Timing: after-hours filing today, with VYD2311 top-line data expected late Q3 2026

Background

This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and clinical/program updates for Invivyd’s pemivibart (PEMGARDA) and VYD2311 (DECLARATION and LIBERTY) plus other pipeline items.

Company-level read

Ticker impact

$IVVDNeutralMedium confidence
Context

Invivyd reported Q2 2026 PEMGARDA net product revenue of $14.3M (+21% YoY) and disclosed cash of $160.1M plus VYD2311 top-line timing into late Q3 2026.

Expected impact

Moderate two-sided reaction risk: upside from growth and clearer VYD2311 timelines, downside from PEMGARDA EUA termination and higher R&D burn.

Evidence & confidence

The filing is a primary disclosure (8-K with results and program updates). It includes both positive commercial growth and negative regulatory overhang (EUA termination notice), plus a concrete schedule for pivotal readouts.

Market effects

Reinforces ongoing investor focus on COVID-era monoclonal antibody economics, regulatory pathways, and pivot timelines toward next-gen programs.

Limited, company-specific biotech update with no stated regional policy or procurement linkage.

Primarily US regulatory and clinical-trial driven; global revenue implications depend on any post-EUA commercialization strategy.

Counterpoint

PEMGARDA growth may be less durable given the disclosed EUA termination notice, so the market may discount near-term revenue momentum.

Key entities

  • Invivyd, Inc.

    Nasdaq-listed biotech reporting Q2 2026 results, cash position, and pivotal trial timelines for VYD2311.

  • PEMGARDA (pemivibart)

    Commercial monoclonal antibody; company reported Q2 net product revenue and disclosed EUA termination advanced notice.

  • VYD2311

    Monoclonal antibody prophylaxis program; pivotal DECLARATION and Phase 3 LIBERTY trials with top-line timing into late Q3 2026.

  • FDA

    Company is in dialogue on appropriate next steps following EUA termination advanced notice for PEMGARDA.

Related articles

$IVVDMed

Invivyd Posts Wider Loss In Q3 As Operating Expenses Rise

Invivyd, Inc. (IVVD) reported a wider Q3 net loss of $33.47 million, up from $10.47 million YoY, due to higher operating expenses. Revenue rose 18% to $15.45 million. The company provided updates on its pipeline, including VYD2311 for COVID-19 and VMS063 for measles, and announced leadership changes. Cash reserves totaled $126.40 million.

$IVVDHigh

Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

$IVVDMedAI 8/10

Invivyd presents preclinical data on measles antibody candidate

Invivyd (NASDAQ:IVVD) presented preclinical data for its measles antibody candidate VMS063 at IDWeek 2026, showing antiviral activity against measles virus variants. The company plans to scale up manufacturing for clinical development in 2027. There are currently no FDA-approved treatments for measles, with U.S. cases nearly double in 2026 compared to 2025, according to Invivyd.

$IVVDLow

Invivyd, Inc. (IVVD) Unveils Preclinical Data for Measles mAb VMS063

Invivyd, Inc. (IVVD) presented preclinical data for VMS063, a novel monoclonal antibody for measles, showing in vitro activity against contemporary virus variants. The company is scaling up production for clinical development in 2027. There are currently no FDA-approved treatments for measles, and the U.S. is experiencing a surge in cases.

$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.